Diagnostic Center | May 20, 2023
Moderna presents Phase 1/2 of MRNA-3927at 2023 ASGCT Meeting
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
The divested brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands
Point-of-Care solution to facilitate clinicians in quick and effective decision making
Subscribe To Our Newsletter & Stay Updated
